Sequential, cycling maintenance therapy for post transplant multiple myeloma

Top of pageAbstract High-dose chemotherapy with autologous stem cell transplantation in patients with newly diagnosed multiple myeloma can prolong survival but is not curative. Maintenance therapy post transplant may prolong the disease-free interval and impact overall survival. We have conducted a phase II pilot study of 28 post transplant myeloma patients treated with a sequential, cycling maintenance regimen. The regimen was designed to include a variety of active myeloma agents chosen for ease of administration to enhance patient compliance and scheduled sequentially to minimize toxicity. The 12-month cycling schedule included dexamethasone (months 1–3); melphalan and prednisone (months 4, 5); cyclophosphamide and prednisone (months 6, 7); -interferon (months 8–10); followed by a drug holiday (months 11, 12). The regimen was generally well tolerated with five patients developing reversible grade III–IV toxicity (diabetes-induced hyperglycemia in four, neutropenia in one). There was one toxic death on study due to non-neutropenic pneumonia and sepsis. Median event-free survival from transplant was 36.9 months (95% CI 23.6 – upper limit not yet reached) with median overall survival not yet reached at a median follow-up of 44 months. This concept of cycling, sequential maintenance with various agents, perhaps including newer biological, targeted agents, warrants further investigation in multiple myeloma. Keywords: multiple myeloma, maintenance therapy, alkylating agents, interferon, glucocorticosteroids, stem cell transplant